Nuvation Bio Inc. reports news as a global oncology company developing and commercializing targeted cancer therapies. Its updates center on IBTROZI® (taletrectinib), an oral, CNS-active, selective next-generation ROS1 inhibitor approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, as well as regulatory submissions, clinical data from TRUST studies, guideline inclusion, and commercialization activity.
Company news also covers safusidenib, a brain-penetrant IDH1 inhibitor for IDH1-mutant glioma, and Nuvation Bio's drug-drug conjugate program. Recurring corporate items include licensing and collaboration arrangements, product-rights updates, investor conference participation, operating results, financial results, capital-structure disclosures, and governance matters.
Nuvation Bio (NUVB) received FDA approval of a supplemental New Drug Application for IBTROZI (taletrectinib) updating efficacy data in TKI‑naïve advanced ROS1‑positive NSCLC.
The U.S. label now includes a median duration of response of 49.7 months in TKI‑naïve patients from the Phase 2 TRUST‑I study, based on a median follow‑up of 51 months and an additional 14 months of data from TRUST‑I and TRUST‑II as of an August 2025 cutoff. The update was granted four months ahead of the PDUFA date and made with no changes to the safety sections of the label and no new safety signals identified, confirming the existing safety profile. IBTROZI already has full FDA approval (June 2025) for adult patients with locally advanced or metastatic ROS1+ NSCLC and is approved in Japan and China, while MAAs are under review by the EMA and the UK MHRA.
Nuvation Bio (NUVB) reported new subgroup analyses from the TRUST-I and TRUST-II trials of IBTROZI (taletrectinib) in advanced ROS1+ NSCLC.
Pooled TKI-naïve data previously showed a confirmed objective response rate (ORR) of 89.8% and median duration of response (DOR) of 49.7 months. New WCLC 2026 analyses showed ORR of 90.0% in TKI-naïve patients who had prior chemotherapy (n=30) versus 89.8% without prior chemotherapy (n=127), with median DOR of 48.3 and 54.3 months, respectively. Efficacy was similar across ROS1 fusion partners: in TKI-naïve patients, ORR was 89.5% for CD74 fusions and 88.9% for non-CD74, with median DOR of 44.8 and 43.3 months and median PFS of 46.1 and 44.6 months.
With longer follow-up, no new safety signals were seen; common adverse events included liver enzyme elevations, diarrhea, nausea and vomiting.
Nuvation Bio (NUVB) will participate in Citi's 2026 Biopharma Back to School Conference and the 2026 Cantor Global Healthcare Conference in New York in September 2026.
Founder, President and CEO David Hung, M.D., and CFO Philippe Sauvage will join fireside chats and one-on-one meetings. Webcasts of both fireside chats, and 90-day archives, will be accessible via the Investor Relations section of Nuvation Bio's website.
Nuvation Bio (NYSE: NUVB) announced that the U.S. FDA has granted Fast Track Designation for safusidenib, its investigational oral, brain-penetrant selective inhibitor of mutant IDH1, for the treatment of IDH1-mutant glioma.
According to Nuvation Bio, Fast Track status is intended to facilitate development and expedite review for serious conditions with unmet medical need and may allow more frequent FDA interactions and rolling review of a marketing application, potentially shortening time to patients if future data are positive.
The designation was granted based on favorable data from the safusidenib program, including updated Phase 2 J201 results: at a median follow-up of 38.8 months, treatment showed a confirmed objective response rate of 51.9%, median progression-free survival not yet reached, and a 36‑month progression-free survival rate of 79.1%, with no new safety signals identified.
Safusidenib is being further evaluated in the pivotal Phase 3 SIGMA (G203) study in IDH1-mutant astrocytoma with high-risk features (approximately 300 patients) and in additional Phase 2 and Phase 3 studies, including settings where there are limited or no approved targeted options.
Nuvation Bio (NYSE: NUVB) reported second quarter 2026 total revenue of $31.7 million, including $23.2 million in net product revenue from IBTROZI and $8.5 million from collaboration and license agreements. Net loss was $62.8 million, or $(0.18) per basic and diluted share.
IBTROZI net product revenue grew about 25% QoQ, with ~160 new U.S. patient starts and ~85% of them TKI‑naïve. As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $661.0 million, excluding $36.5 million in overallotment proceeds received in July. In July, the company also closed a 0.75% Convertible Senior Notes offering with estimated net proceeds of $279.1 million, supported by capped calls to mitigate dilution.
Nuvation Bio highlighted positive updated Phase 2 data for safusidenib in grade 2 IDH1‑mutant glioma, including a 51.9% ORR and 79.1% 36‑month PFS rate, and announced an expanded global clinical program. Regulatory and guideline milestones for IBTROZI included FDA sNDA acceptance with a January 4, 2027 target action date, MHRA validation of a UK MAA, and inclusion in NCCN CNS cancer guidelines for ROS1+ NSCLC with brain metastases.
Nuvation Bio (NYSE: NUVB) will present new subgroup analyses from its pivotal Phase 2 TRUST-I and TRUST-II studies of IBTROZI (taletrectinib) in adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) at the 2026 WCLC in Seoul and the 2026 ESMO Congress in Madrid.
The presentations will examine consistency of efficacy and safety across key subgroups, including patients previously treated with earlier-generation ROS1 inhibitors and after prior entrectinib exposure. According to Nuvation Bio, IBTROZI is an oral, CNS-active, next-generation ROS1 inhibitor, approved by the U.S. FDA on June 11, 2025, and being evaluated in the global TRUST clinical program, which includes multiple Phase 2 and Phase 3 registrational studies in advanced and early-stage ROS1+ NSCLC.
Nuvation Bio (NYSE: NUVB) will host a conference call and webcast on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a business update. The live and archived webcast will be available via the Investor Relations section of its website.
Nuvation Bio (NYSE: NUVB) reported updated long-term Phase 2 (J201) data for safusidenib in chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma, showing a centrally assessed confirmed overall response rate of 51.9% and a 36-month progression-free survival rate of 79.1% at a median 38.8-month follow-up in 27 patients in Japan. Median progression-free survival was not reached, only one prior responder had subsequent disease progression, and no new safety signals were identified.
According to Nuvation Bio, safusidenib’s clinical program is being expanded with two additional trials: the pivotal Phase 3 G307 study in approximately 140 newly diagnosed grade 2 IDH1-mutant glioma patients outside the U.S., and the Phase 2 G209 study in up to 40 U.S. patients with grade 2 or 3 IDH1-mutant glioma whose disease has progressed after vorasidenib. These studies build on the ongoing pivotal Phase 3 SIGMA (G203) trial in approximately 300 patients with IDH1-mutant astrocytoma with high-risk features and an exploratory cohort of about 40 patients with grade 3 IDH1-mutant oligodendroglioma.
Nuvation Bio (NYSE: NUVB) reported full exercise of underwriters’ $37.5 million greenshoe option in its 0.75% Convertible Senior Notes due 2032 offering. Total aggregate principal reached $287.5 million. Nuvation Bio expects net proceeds of about $277.6 million after fees and expenses.
The company entered additional capped call transactions with a $10.4580 cap price, an 80% premium to the June 25, 2026 share price, spending approximately $2.2 million. Remaining proceeds are earmarked for general corporate purposes, including working capital and operating needs.
Nuvation Bio (NYSE: NUVB) announced that the UK MHRA has validated the Marketing Authorisation Application for taletrectinib to treat advanced ROS1-positive non-small cell lung cancer (NSCLC). The MAA, filed via the International Recognition Procedure, will now undergo full review.
The submission is based on pivotal Phase 2 TRUST-I and TRUST-II data. A separate MAA is under review by the European Medicines Agency, and additional filings are planned for Canada and other Eisai-licensed regions. Taletrectinib already has approvals for ROS1+ NSCLC in the US, Japan and China.